Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | 1,3-beta-glucan synthase component protein | 0.0485 | 0.6535 | 0.5 |
Mycobacterium ulcerans | hydrolase | 0.021 | 0 | 0.5 |
Loa Loa (eye worm) | matrixin family protein | 0.0382 | 0.409 | 0.8334 |
Echinococcus granulosus | matrix metallopeptidase 7 M10 family | 0.0627 | 0.989 | 0.5 |
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.0382 | 0.409 | 1 |
Brugia malayi | Matrixin family protein | 0.0417 | 0.4908 | 1 |
Mycobacterium tuberculosis | Probable peptidoglycan hydrolase | 0.021 | 0 | 0.5 |
Mycobacterium leprae | PROBABLE HYDROLASE | 0.021 | 0 | 0.5 |
Trypanosoma brucei | RNA helicase, putative | 0.0631 | 1 | 0.5 |
Brugia malayi | Hemopexin family protein | 0.0244 | 0.0818 | 0.1666 |
Loa Loa (eye worm) | matrixin family protein | 0.0417 | 0.4908 | 1 |
Onchocerca volvulus | Matrilysin homolog | 0.0382 | 0.409 | 1 |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.0627 | 0.989 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MED (functional) | <= 0.78 mg kg-1 | Minimum effective dose (MED) against leukemia P388 in CDF1 mice | ChEMBL. | 7241508 |
Optimal dose (functional) | = 12.5 mg kg-1 | Optimal dose of the compound against leukemia P388 in CDF1 mice | ChEMBL. | 7241508 |
T/C (functional) | = 128 % | Antitumor activity against leukemia P388 in CDF1 mice | ChEMBL. | 7241508 |
T/C (functional) | = 184 % | Antitumor activity against leukemia P388 in CDF1 mice | ChEMBL. | 7241508 |
TI (ADMET) | = 16 | Therapeutic index was determined against leukemia P388 cells in mice | ChEMBL. | 7241508 |
Toxic dose (functional) | >= 50 mg kg-1 | Toxic dose against leukemia P388 in CDF1 mice | ChEMBL. | 7241508 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.